Merck Publishes Annual Corporate Responsibility Report
November 02 2017 - 8:00AM
Business Wire
Report Highlights New Environmental
Sustainability Goals and Impact on Global Health
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, today published its 2016/2017
Corporate Responsibility Report. The report reflects the company’s
performance in the areas of Access to Health, Employees,
Environmental Sustainability and Ethics & Transparency.
“We continue to push the boundaries of science with the hope and
expectation that our innovative solutions will lead to better
health for generations to come,” said Kenneth C. Frazier, chairman
and chief executive officer, Merck. “That same commitment to
overcoming the world’s greatest health challenges extends to how we
operate as a responsible company -- building a sustainable business
that contributes to a healthier world.”
The report highlights the progress Merck has made toward
creating social and economic value for the company and its
stakeholders. The report also highlights the company’s new
environmental sustainability goals and its continuing support of
the United Nations’ Sustainable Development Goals (SDGs), the
international community’s aspirations for improving the lives of
the world’s poorest people by 2030.
Additional highlights from the report include how Merck is:
- Addressing 88 percent of the top 20
global burdens of disease with our products and pipeline, including
cancer, HIV, diabetes and Alzheimer’s disease;
- Improving access to quality maternal
health care and family planning services for nearly six million
women around the world through Merck for Mothers, our 10-year, $500
million global initiative to end preventable maternal deaths;
- Working to achieve 12 new environmental
sustainability goals to manage the impact of our operations, supply
chain, products and packaging;
- Increasing our use of diverse suppliers
by nearly 60 percent throughout 2016, totaling more than $1 billion
with companies owned by members of minority groups, women, veterans
and individuals who are disabled or identify as LGBT;
- Continuing to develop a more diverse
and inclusive workforce: in 2016, more than half of our new hires
worldwide were women, and in the United States, 37 percent were
from under-represented groups.
The company continues to use several external guidelines and
measurement frameworks to inform the scope of its reporting,
including the GRI Sustainability Reporting Standards, the
Sustainable Development Goals, the Access to Medicine Index and the
United Nations Global Compact.
Learn more about Merck’s approach to Corporate Responsibility
and progress on key initiatives in the 2016/2017 Corporate Responsibility Report.
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer’s disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us on Twitter, Facebook,
Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., U.S.A.
This news release of Merck & Co., Inc., Kenilworth, N.J.,
U.S.A. (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2016
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171102005356/en/
For Merck:Media:Doris Li, 908-740-1903orJeanine Clemente,
908-740-6268orInvestors:Teri Loxam, 908-740-1986orAmy Klug,
908-740-1898
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024